Gilva is a biopharmaceutical company focused on the development of small molecule drugs for unmet medical needs, especially in rare diseases.
Gilva has a robust drug discovery and development platform. This platform effectively optimizes the efficacy, druggability or safety of drugs based on the structure-activity relationship (SAR). Gilva also has a team with extensive experience in drug development, which can improve the efficiency of drug discovery and reduce development risks.

Gilva focuses on new drug development without the constraints of a traditional laboratory setup, characterized by a lightweight asset structure, low investment, and high cost-effectiveness. The company leverages a robust biological theory foundation to develop products with first-in-class or best-in-class potential. Currently, Gilva is dedicated to exploring HDAC inhibitors, utilizing accumulated expertise and drug development experience to focus on unmet clinical needs in disease therapeutics.